Tenaya Therapeutics (TNYA) Stock Price, News & Analysis

Company Overview

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $1.95 to $2.16
• 50-Day Range: $1.64 to $2.76
• 52-Week Range: $1.61 to $7.01
• Volume: 3.71 million shs
• Average Volume: 824,387 shs
• Market Capitalization: $160.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.75
• Consensus Rating: Buy

Tenaya Therapeutics Stock Analysis - MarketRank™

Tenaya Therapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 203rd out of 973 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Tenaya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tenaya Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tenaya Therapeutics are expected to grow in the coming year, from ($1.37) to ($1.31) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tenaya Therapeutics is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tenaya Therapeutics is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tenaya Therapeutics has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.99% of the float of Tenaya Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tenaya Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tenaya Therapeutics has recently increased by 7.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tenaya Therapeutics does not currently pay a dividend.

Dividend Growth

Tenaya Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.99% of the float of Tenaya Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tenaya Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tenaya Therapeutics has recently increased by 7.38%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.85

News Sentiment

Tenaya Therapeutics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for Tenaya Therapeutics this week, compared to 2 articles on an average week.

Search Interest

22 people have searched for TNYA on MarketBeat in the last 30 days.

MarketBeat Follows

14 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tenaya Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $56,468.00 in company stock.

Percentage Held by Insiders

32.76% of the stock of Tenaya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

90.54% of the stock of Tenaya Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TNYA Stock Analysis - Frequently Asked Questions

How have TNYA shares performed this year?

Tenaya Therapeutics' stock was trading at $3.24 at the start of the year. Since then, TNYA stock has decreased by 37.7% and is now trading at $2.02.
View the best growth stocks for 2024 here.

How were Tenaya Therapeutics' earnings last quarter?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) posted its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.07.

When did Tenaya Therapeutics IPO?

Tenaya Therapeutics (TNYA) raised $150 million in an IPO on Friday, July 30th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

Who are Tenaya Therapeutics' major shareholders?

Top institutional shareholders of Tenaya Therapeutics include FMR LLC (1.70%), abrdn plc (0.70%), GSA Capital Partners LLP (0.19%) and Walleye Capital LLC (0.09%). Insiders that own company stock include Group Gp Lp Column III, David V Goeddel, Deepak Srivastava, Timothy Hoey, Faraz Ali, Whittemore Tingley and Chihiro Saito.
View institutional ownership trends.

How do I buy shares of Tenaya Therapeutics?

Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Tenaya Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tenaya Therapeutics investors own include Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 11/14/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/17/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TNYA
• CUSIP: N/A
• CIK: 1858848
• Web: www.tenayatherapeutics.com
• Phone: 650-825-6990
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.75
• High Stock Price Target: $18.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +630.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-124,080,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -86.17%
• Return on Assets: -71.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.27
• Quick Ratio: 5.27

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.42 per share
• Price / Book: 1.42

Miscellaneous

• Outstanding Shares: 79,220,000
• Free Float: 53,268,000
• Market Cap: $160.02 million
• Optionable: Optionable
• Beta: 2.34